RAPS RAC-GS - Questions & Answers
Free preview · every answer includes a full explanation
Product page: https://prepkeys.com/rac-gs.html
A company's product was approved by a regulatory authority with the condition that further studies must be completed prior to full approval of the product.
To minimize product-associated risk to patients during the period of conditional approval, what is the LEAST effective way to achieve this goal?
A global company is developing a sophisticated implantable medical device that is coated with antibiotics and biologics to enhance its efficacy. The product is marketed in Country X. where it is regulated as a medical device. The same product, without theantibiotics and biologics, is marketed as a medical device in Country Y. The company is proposing to start marketing the coated device in Country Y.
Which regulatory approach should the company propose?
Company X acquires Company Y. Both companies produce pharmaceuticals distributed globally. A regulatory authority requires that all labeling for Company Y's products be converted to Company X within three months. The regulatory affairs professional at Company X concludes that it is not feasible to meet this request within the time frame.
Which is the FIRST step that the regulatory affairs professional at Company X should take to address the situation?
A protocol for a pivotal registration trial of a new product is submitted to a major regulatory authority for review and approval. The regulatory authority issues the company a written commitment that if the studies are completed as outlined in the protocol and the results meet the pre-specified criteria for efficacy and safety, the product will be approved.
During the final week of the review of the marketing application, which has fully met all pre-specified criteria, the company receives a letter from the regulatory authority stating that it no longer believes that
the product will be approved based on a recent withdrawal of a similar product in another country.
What is the BEST response?
In order to develop a global drug product, what is the MOST important environmental characteristic to consider in the country of intended use?
Company X encounters challenges in the global life cycle management of its medical devices.
Which of the following Is MOST appropriate for improving product life cycle management?
Which term does NOT describe the same concept as the others?
A process is ultimately validated to ensure which of the following?
Which of the following is an example of an acceptable statement for an advertisement of an approved arthritis medication?
After numerous failed attempts to decrease an identified risk in a medical device to an acceptable level, the medical device continues to have unacceptable risks. However, the development team wants to continue development.
Which is the BEST recommendation to make in this situation?